tv.qiagenbioinformatics.com marketingbiox@qiagen.com https://tv.qiagenbioinformatics.com Watch tutorials, interviews and much more on our web based TV channel! en-us Visualplatform http://blogs.law.harvard.edu/tech/rss tv.qiagenbioinformatics.com CLC bio TV Watch tutorials, interviews and much more on our web based TV channel! clc bio tv, bioinformatics, genomics, research episodic no https://tv.qiagenbioinformatics.com/files/rv0.0/sitelogo.gif https://tv.qiagenbioinformatics.com http://tv.qiagenbioinformatics.com/photo/123800918/from-targets-to-treatments <p><p>The early stages of drug development are inherently high-risk; molecule screening, target evaluation and lead refinement can take years and cost millions of dollars – often have little to show for the effort. Indication expansion and drug repurposing can open new avenues of possibility, after careful evaluation of the relationships between the drug, its targets and the new disease context. These connections can be uncovered by mining curated, causal knowledge graphs, which inform smarter target identification.</p><p>&nbsp;</p><p>Learn how to evaluate targets and drugs in this oncology-focused webinar, which examines BRAF as a target in multiple myeloma. Also, we’ll evaluate different drugs in clinical trials with an analysis that covers the GOT-IT assessment blocks for drug evaluation. These blocks, developed by the GOT-IT (Guidelines On Target Assessment for Innovative Therapeutics) working group, are part of a target assessment framework that supports robust, reproducible data.</p><p>We’ll cover how to:</p><ul><li><p>- Apply the GOT-IT framework to target evaluation and indication expansion</p></li><li><p>- Uncover causal relationships between existing drugs and new diseases with our curated knowledge graphs</p></li><li><p>- Make informed decisions based on concrete data, including toxicity, adverse events and competing drugs in clinical trials</p></li></ul><p></p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/123800918/from-targets-to-treatments"><img src="http://tv.qiagenbioinformatics.com/64968577/123800918/afba09610d30f970942b3829d508cc1e/standard/download-10-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/123800918 Fri, 20 Feb 2026 09:23:25 GMT From targets to treatments: Data-driven drug discovery across therapeutic areas The early stages of drug development are inherently high-risk; molecule screening, target evaluation and lead refinement can take years and cost millions of dollars – often have little to show for the effort. Indication expansion and drug repurposing can open new avenues of possibility, after careful evaluation of the relationships between the drug, its targets and the new disease context. These connections can be uncovered by mining curated, causal knowledge graphs, which inform smarter target identification.Learn how to evaluate targets and drugs in this oncology-focused webinar, which examines BRAF as a target in multiple myeloma. Also, we’ll evaluate different drugs in clinical trials with an analysis that covers the GOT-IT assessment blocks for drug evaluation. These blocks, developed by the GOT-IT (Guidelines On Target Assessment for Innovative Therapeutics) working group, are part of a target assessment framework that supports robust, reproducible data.We’ll cover how to:- Apply the GOT-IT framework to target evaluation and indication expansion- Uncover causal relationships between existing drugs and new diseases with our curated knowledge graphs- Make informed decisions based on concrete data, including toxicity, adverse events and competing drugs in clinical trials The early stages of drug development are inherently high-risk; molecule screening, target evaluation and lead refinement can take years and cost millions of dollars – often have little to show for the effort. Indication expansion and drug... tv.qiagenbioinformatics.com 59:25 <p><p>The early stages of drug development are inherently high-risk; molecule screening, target evaluation and lead refinement can take years and cost millions of dollars – often have little to show for the effort. Indication expansion and drug repurposing can open new avenues of possibility, after careful evaluation of the relationships between the drug, its targets and the new disease context. These connections can be uncovered by mining curated, causal knowledge graphs, which inform smarter target identification.</p><p>&nbsp;</p><p>Learn how to evaluate targets and drugs in this oncology-focused webinar, which examines BRAF as a target in multiple myeloma. Also, we’ll evaluate different drugs in clinical trials with an analysis that covers the GOT-IT assessment blocks for drug evaluation. These blocks, developed by the GOT-IT (Guidelines On Target Assessment for Innovative Therapeutics) working group, are part of a target assessment framework that supports robust, reproducible data.</p><p>We’ll cover how to:</p><ul><li><p>- Apply the GOT-IT framework to target evaluation and indication expansion</p></li><li><p>- Uncover causal relationships between existing drugs and new diseases with our curated knowledge graphs</p></li><li><p>- Make informed decisions based on concrete data, including toxicity, adverse events and competing drugs in clinical trials</p></li></ul><p></p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/123800918/from-targets-to-treatments"><img src="http://tv.qiagenbioinformatics.com/64968577/123800918/afba09610d30f970942b3829d508cc1e/standard/download-10-thumbnail.jpg" width="75" height=""/></a></p> bkb discovery http://tv.qiagenbioinformatics.com/photo/117733127/investigate-critical-biological <p><p>Pathways and knowledge graphs have provided valuable insights into disease pathology, toxicology, target safety assessment, drug MOA and biological mechanisms in general. Though this is not possible without a high quality, reliable database. QIAGEN Knowledgebase is a comprehensive database with causal reasoning that is regularly updated from trusted peer-review publications and other sources using both high quality manual curation and utilizing AI/ML approaches.</p><p>In this webinar the trainer will</p><ul><li><p>Introduce the QIAGEN Knowledgebase</p></li><li><p>Demonstrate how the user can take advantage of an easy-to-use graphical interface to study pathways and networks of interest</p></li><li><p>Show how this database can be accessed programmatically for applications such as knowledge graph investigation</p></li></ul></p><p><a href="http://tv.qiagenbioinformatics.com/photo/117733127/investigate-critical-biological"><img src="http://tv.qiagenbioinformatics.com/64968555/117733127/bc82603092b56e32746bc980d6b6a52a/standard/download-10-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/117733127 Mon, 27 Oct 2025 14:07:01 GMT Investigate critical biological mechanisms using pathways and knowledge graphs Pathways and knowledge graphs have provided valuable insights into disease pathology, toxicology, target safety assessment, drug MOA and biological mechanisms in general. Though this is not possible without a high quality, reliable database. QIAGEN Knowledgebase is a comprehensive database with causal reasoning that is regularly updated from trusted peer-review publications and other sources using both high quality manual curation and utilizing AI/ML approaches.In this webinar the trainer willIntroduce the QIAGEN KnowledgebaseDemonstrate how the user can take advantage of an easy-to-use graphical interface to study pathways and networks of interestShow how this database can be accessed programmatically for applications such as knowledge graph investigation Pathways and knowledge graphs have provided valuable insights into disease pathology, toxicology, target safety assessment, drug MOA and biological mechanisms in general. Though this is not possible without a high quality, reliable database.... tv.qiagenbioinformatics.com 54:31 <p><p>Pathways and knowledge graphs have provided valuable insights into disease pathology, toxicology, target safety assessment, drug MOA and biological mechanisms in general. Though this is not possible without a high quality, reliable database. QIAGEN Knowledgebase is a comprehensive database with causal reasoning that is regularly updated from trusted peer-review publications and other sources using both high quality manual curation and utilizing AI/ML approaches.</p><p>In this webinar the trainer will</p><ul><li><p>Introduce the QIAGEN Knowledgebase</p></li><li><p>Demonstrate how the user can take advantage of an easy-to-use graphical interface to study pathways and networks of interest</p></li><li><p>Show how this database can be accessed programmatically for applications such as knowledge graph investigation</p></li></ul></p><p><a href="http://tv.qiagenbioinformatics.com/photo/117733127/investigate-critical-biological"><img src="http://tv.qiagenbioinformatics.com/64968555/117733127/bc82603092b56e32746bc980d6b6a52a/standard/download-10-thumbnail.jpg" width="75" height=""/></a></p> bkb http://tv.qiagenbioinformatics.com/photo/115459797/how-to-triage-drug-targets-with-1 <p><p>In the rapidly evolving landscape of drug discovery, the ability to integrate high-quality research findings into knowledge graphs is paramount. For over twenty years, our scientists have curated the relationships between genes, drugs, diseases, and pathways to power Ingenuity Pathway Analysis. Now, these data are available via our QIAGEN Biomedical KB-HD, which provides direct access to flat files, SQL APIs in Python and R, and the ability to export knowledge graph objects for analysis in Neo4j. </p><p>In this talk, we will explore how to use this rich data resource to:</p><p>• Aggregate relevant findings across our comprehensive disease and gene ontologies</p><p>• Cross-reference clinical trial results to focus your research on genes upstream or downstream of known drug targets</p><p>• Filter causal relationships by the directionality of observed effects</p><p>• Combine the above methods to accelerate the drug discovery process</p><p>By demonstrating the underlying database live, we will show how the high-quality curated biomedical knowledge bases can be rapidly deployed, as well as how the underlying schema and ontologies could serve as a scaffold for integrating your own research. Overall, this demonstration will show the critical role of knowledge graphs in finding viable drug targets while avoiding potential adverse outcomes and toxicity.</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/115459797/how-to-triage-drug-targets-with-1"><img src="http://tv.qiagenbioinformatics.com/64968570/115459797/c1f9a917c72bcedc269dd5ba3d9b609f/standard/download-10-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/115459797 Wed, 20 Aug 2025 22:19:43 GMT How to triage drug targets with curated, causal relationships data In the rapidly evolving landscape of drug discovery, the ability to integrate high-quality research findings into knowledge graphs is paramount. For over twenty years, our scientists have curated the relationships between genes, drugs, diseases, and pathways to power Ingenuity Pathway Analysis. Now, these data are available via our QIAGEN Biomedical KB-HD, which provides direct access to flat files, SQL APIs in Python and R, and the ability to export knowledge graph objects for analysis in Neo4j. In this talk, we will explore how to use this rich data resource to:• Aggregate relevant findings across our comprehensive disease and gene ontologies• Cross-reference clinical trial results to focus your research on genes upstream or downstream of known drug targets• Filter causal relationships by the directionality of observed effects• Combine the above methods to accelerate the drug discovery processBy demonstrating the underlying database live, we will show how the high-quality curated biomedical knowledge bases can be rapidly deployed, as well as how the underlying schema and ontologies could serve as a scaffold for integrating your own research. Overall, this demonstration will show the critical role of knowledge graphs in finding viable drug targets while avoiding potential adverse outcomes and toxicity. In the rapidly evolving landscape of drug discovery, the ability to integrate high-quality research findings into knowledge graphs is paramount. For over twenty years, our scientists have curated the relationships between genes, drugs, diseases,... tv.qiagenbioinformatics.com 59:54 <p><p>In the rapidly evolving landscape of drug discovery, the ability to integrate high-quality research findings into knowledge graphs is paramount. For over twenty years, our scientists have curated the relationships between genes, drugs, diseases, and pathways to power Ingenuity Pathway Analysis. Now, these data are available via our QIAGEN Biomedical KB-HD, which provides direct access to flat files, SQL APIs in Python and R, and the ability to export knowledge graph objects for analysis in Neo4j. </p><p>In this talk, we will explore how to use this rich data resource to:</p><p>• Aggregate relevant findings across our comprehensive disease and gene ontologies</p><p>• Cross-reference clinical trial results to focus your research on genes upstream or downstream of known drug targets</p><p>• Filter causal relationships by the directionality of observed effects</p><p>• Combine the above methods to accelerate the drug discovery process</p><p>By demonstrating the underlying database live, we will show how the high-quality curated biomedical knowledge bases can be rapidly deployed, as well as how the underlying schema and ontologies could serve as a scaffold for integrating your own research. Overall, this demonstration will show the critical role of knowledge graphs in finding viable drug targets while avoiding potential adverse outcomes and toxicity.</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/115459797/how-to-triage-drug-targets-with-1"><img src="http://tv.qiagenbioinformatics.com/64968570/115459797/c1f9a917c72bcedc269dd5ba3d9b609f/standard/download-10-thumbnail.jpg" width="75" height=""/></a></p> bkb http://tv.qiagenbioinformatics.com/photo/112699238/identifying-new-drug-targets-and <p><p>QIAGEN Biomedical KB-HD is the high-quality, expert-curated biomedical knowledge base that powers QIAGEN Ingenuity Pathway Analysis. This webinar will focus on proposing new drug targets and biomarkers using the Neo4J graph database management system by mining the Biomedical KB-HD knowledge graph.</p><p>&nbsp;</p><p>You'll learn how to:</p><p>&nbsp;</p><p>• Associate a drug target with a disease indication of interest</p><p>• Identify causal intermediates that can serve as potential drug targets</p><p>• Identify biomarkers associated with the disease indication in the context of the mechanistic network being studied</p><p>• Study drugs and genomics variants associated with intermediates</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/112699238/identifying-new-drug-targets-and"><img src="http://tv.qiagenbioinformatics.com/64968558/112699238/14413c91bb59b6b392d30855d9a5ac07/standard/download-8-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/112699238 Mon, 12 May 2025 14:25:09 GMT Identifying new drug targets and biomarkers for a disease of interest using... QIAGEN Biomedical KB-HD is the high-quality, expert-curated biomedical knowledge base that powers QIAGEN Ingenuity Pathway Analysis. This webinar will focus on proposing new drug targets and biomarkers using the Neo4J graph database management system by mining the Biomedical KB-HD knowledge graph.You'll learn how to:• Associate a drug target with a disease indication of interest• Identify causal intermediates that can serve as potential drug targets• Identify biomarkers associated with the disease indication in the context of the mechanistic network being studied• Study drugs and genomics variants associated with intermediates QIAGEN Biomedical KB-HD is the high-quality, expert-curated biomedical knowledge base that powers QIAGEN Ingenuity Pathway Analysis. This webinar will focus on proposing new drug targets and biomarkers using the Neo4J graph database management... tv.qiagenbioinformatics.com 55:02 <p><p>QIAGEN Biomedical KB-HD is the high-quality, expert-curated biomedical knowledge base that powers QIAGEN Ingenuity Pathway Analysis. This webinar will focus on proposing new drug targets and biomarkers using the Neo4J graph database management system by mining the Biomedical KB-HD knowledge graph.</p><p>&nbsp;</p><p>You'll learn how to:</p><p>&nbsp;</p><p>• Associate a drug target with a disease indication of interest</p><p>• Identify causal intermediates that can serve as potential drug targets</p><p>• Identify biomarkers associated with the disease indication in the context of the mechanistic network being studied</p><p>• Study drugs and genomics variants associated with intermediates</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/112699238/identifying-new-drug-targets-and"><img src="http://tv.qiagenbioinformatics.com/64968558/112699238/14413c91bb59b6b392d30855d9a5ac07/standard/download-8-thumbnail.jpg" width="75" height=""/></a></p> bkb http://tv.qiagenbioinformatics.com/photo/103182479/assessing-drug-safety-with-qiagen <p>Are you a healthcare professional, clinical researcher or data scientist interested in drug safety research? If so, you know how vital understanding a drug’s adverse effects is to maximize its effect while minimizing its risks. This webinar will show how the QIAGEN Biomedical KB-AI knowledge graph can be used to explore scientific and pharmacovigilance data. Focusing on immune checkpoint inhibitors (ICIs), we will also demonstrate how Neo4j and Python can be combined to query, visualize and analyze this data effectively.</p> <p>We’ll cover the following:</p> <p>• Drug safety profiling in Biomedical KB-AI<br /> • Pharmacovigilance case study of ICIs: Pembrolizumab<br /> • Comparative analysis of ICIs for comprehensive safety monitoring.</p><p><a href="http://tv.qiagenbioinformatics.com/photo/103182479/assessing-drug-safety-with-qiagen"><img src="http://tv.qiagenbioinformatics.com/64968559/103182479/620477f68a24d2d6c6519d98bd3f3d8e/standard/download-7-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/103182479 Wed, 24 Jul 2024 13:57:55 GMT Assessing drug safety with QIAGEN Biomedical KB-AI Are you a healthcare professional, clinical researcher or data scientist interested in drug safety research? If so, you know how vital understanding a drug’s adverse effects is to maximize its effect while minimizing its risks. This webinar will show how the QIAGEN Biomedical KB-AI knowledge graph can be used to explore scientific and pharmacovigilance data. Focusing on immune checkpoint inhibitors (ICIs), we will also demonstrate how Neo4j and Python can be combined to query, visualize and analyze this data effectively. We’ll cover the following: • Drug safety profiling in Biomedical KB-AI • Pharmacovigilance case study of ICIs: Pembrolizumab • Comparative analysis of ICIs for comprehensive safety monitoring. Are you a healthcare professional, clinical researcher or data scientist interested in drug safety research? If so, you know how vital understanding a drug’s adverse effects is to maximize its effect while minimizing its risks. This webinar will... tv.qiagenbioinformatics.com 01:00:04 <p>Are you a healthcare professional, clinical researcher or data scientist interested in drug safety research? If so, you know how vital understanding a drug’s adverse effects is to maximize its effect while minimizing its risks. This webinar will show how the QIAGEN Biomedical KB-AI knowledge graph can be used to explore scientific and pharmacovigilance data. Focusing on immune checkpoint inhibitors (ICIs), we will also demonstrate how Neo4j and Python can be combined to query, visualize and analyze this data effectively.</p> <p>We’ll cover the following:</p> <p>• Drug safety profiling in Biomedical KB-AI<br /> • Pharmacovigilance case study of ICIs: Pembrolizumab<br /> • Comparative analysis of ICIs for comprehensive safety monitoring.</p><p><a href="http://tv.qiagenbioinformatics.com/photo/103182479/assessing-drug-safety-with-qiagen"><img src="http://tv.qiagenbioinformatics.com/64968559/103182479/620477f68a24d2d6c6519d98bd3f3d8e/standard/download-7-thumbnail.jpg" width="75" height=""/></a></p> bkb http://tv.qiagenbioinformatics.com/photo/102661585/accelerating-drug-discovery-with <p>From our talk at BioIT, join QIAGEN Senior Field Application Scientist, Kyle Nilson, PhD, to see how detailed curated knowledge of molecular relationships, datasets and more can quickly drive your understanding of diseases and drive your data-driven drug discovery efforts.</p><p><a href="http://tv.qiagenbioinformatics.com/photo/102661585/accelerating-drug-discovery-with"><img src="http://tv.qiagenbioinformatics.com/64968575/102661585/faf29f53dc95831138d7d79f72d86480/standard/download-6-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/102661585 Wed, 03 Jul 2024 11:13:36 GMT Accelerating drug discovery with comprehensive curated knowledge (Bio-IT talk) From our talk at BioIT, join QIAGEN Senior Field Application Scientist, Kyle Nilson, PhD, to see how detailed curated knowledge of molecular relationships, datasets and more can quickly drive your understanding of diseases and drive your data-driven drug discovery efforts. From our talk at BioIT, join QIAGEN Senior Field Application Scientist, Kyle Nilson, PhD, to see how detailed curated knowledge of molecular relationships, datasets and more can quickly drive your understanding of diseases and drive your... tv.qiagenbioinformatics.com 29:45 <p>From our talk at BioIT, join QIAGEN Senior Field Application Scientist, Kyle Nilson, PhD, to see how detailed curated knowledge of molecular relationships, datasets and more can quickly drive your understanding of diseases and drive your data-driven drug discovery efforts.</p><p><a href="http://tv.qiagenbioinformatics.com/photo/102661585/accelerating-drug-discovery-with"><img src="http://tv.qiagenbioinformatics.com/64968575/102661585/faf29f53dc95831138d7d79f72d86480/standard/download-6-thumbnail.jpg" width="75" height=""/></a></p> bkb http://tv.qiagenbioinformatics.com/photo/101070223/qiagen-biomedical-kb-hd-data-and <p>Ingenuity Pathway Analysis (IPA), currently cited in tens of thousands of publications and used by a large number of biopharmaceutical companies, is backed by QIAGEN Biomedical KB-HD. Accordingly, biomedical relationships knowledge has practically become required for innovative data- and analytics-driven drug discovery. It powers biomedical knowledge graph analysis, artificial intelligence (AI)-driven target identification and many more applications. <p>In this webinar, we will introduce Biomedical KB-HD and how it allows its users to tackle applications that are not feasible with the Ingenuity Pathway Analysis graphical user interface or can be done faster and with more flexibility programmatically. We will demonstrate queries such as</p> <p>• Quickly find the shortest connections between genes/proteins/metabolites of interest in the context of specific disease through queries<br> • Systematically build a network given a short list of genes/proteins/metabolites/chemicals<br> • Recreate a drug mechanism of action</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/101070223/qiagen-biomedical-kb-hd-data-and"><img src="http://tv.qiagenbioinformatics.com/64968566/101070223/d5c09c5e1a5ab2cef09a9d16060c795e/standard/download-10-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/101070223 Tue, 14 May 2024 13:57:00 GMT QIAGEN Biomedical KB-HD: data- and analytics-driven drug discovery Ingenuity Pathway Analysis (IPA), currently cited in tens of thousands of publications and used by a large number of biopharmaceutical companies, is backed by QIAGEN Biomedical KB-HD. Accordingly, biomedical relationships knowledge has practically become required for innovative data- and analytics-driven drug discovery. It powers biomedical knowledge graph analysis, artificial intelligence (AI)-driven target identification and many more applications. In this webinar, we will introduce Biomedical KB-HD and how it allows its users to tackle applications that are not feasible with the Ingenuity Pathway Analysis graphical user interface or can be done faster and with more flexibility programmatically. We will demonstrate queries such as • Quickly find the shortest connections between genes/proteins/metabolites of interest in the context of specific disease through queries • Systematically build a network given a short list of genes/proteins/metabolites/chemicals • Recreate a drug mechanism of action Ingenuity Pathway Analysis (IPA), currently cited in tens of thousands of publications and used by a large number of biopharmaceutical companies, is backed by QIAGEN Biomedical KB-HD. Accordingly, biomedical relationships knowledge has practically... tv.qiagenbioinformatics.com 53:18 <p>Ingenuity Pathway Analysis (IPA), currently cited in tens of thousands of publications and used by a large number of biopharmaceutical companies, is backed by QIAGEN Biomedical KB-HD. Accordingly, biomedical relationships knowledge has practically become required for innovative data- and analytics-driven drug discovery. It powers biomedical knowledge graph analysis, artificial intelligence (AI)-driven target identification and many more applications. <p>In this webinar, we will introduce Biomedical KB-HD and how it allows its users to tackle applications that are not feasible with the Ingenuity Pathway Analysis graphical user interface or can be done faster and with more flexibility programmatically. We will demonstrate queries such as</p> <p>• Quickly find the shortest connections between genes/proteins/metabolites of interest in the context of specific disease through queries<br> • Systematically build a network given a short list of genes/proteins/metabolites/chemicals<br> • Recreate a drug mechanism of action</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/101070223/qiagen-biomedical-kb-hd-data-and"><img src="http://tv.qiagenbioinformatics.com/64968566/101070223/d5c09c5e1a5ab2cef09a9d16060c795e/standard/download-10-thumbnail.jpg" width="75" height=""/></a></p> biomarker biomedical knowledge base bkb omicsoft webinar http://tv.qiagenbioinformatics.com/photo/96931869/gene-set-enrichment-target <p>This 60-minute session will teach you how to effectively use a relationship database for various applications. QIAGEN Biomedical Knowledge Base (Biomedical KB), a database containing high-quality relationship literature findings, the same database backing Ingenuity Pathway Analysis/IPA) will be used, but learnings can also be applied to similar databases. <p>The following points will be discussed:</p> <p>• Gene set enrichment analysis using Biomedical KB<br> • Target validation through Biomedical KB findings<br> • Potential other use cases, queries and applications requested by registrants</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/96931869/gene-set-enrichment-target"><img src="http://tv.qiagenbioinformatics.com/64968568/96931869/e4fbef5d562098e7b4f091dd31fe5fee/standard/download-10-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/96931869 Mon, 15 Apr 2024 09:23:23 GMT Gene set enrichment, target validation and more using high quality biomedical... This 60-minute session will teach you how to effectively use a relationship database for various applications. QIAGEN Biomedical Knowledge Base (Biomedical KB), a database containing high-quality relationship literature findings, the same database backing Ingenuity Pathway Analysis/IPA) will be used, but learnings can also be applied to similar databases. The following points will be discussed: • Gene set enrichment analysis using Biomedical KB • Target validation through Biomedical KB findings • Potential other use cases, queries and applications requested by registrants This 60-minute session will teach you how to effectively use a relationship database for various applications. QIAGEN Biomedical Knowledge Base (Biomedical KB), a database containing high-quality relationship literature findings, the same database... tv.qiagenbioinformatics.com 58:32 <p>This 60-minute session will teach you how to effectively use a relationship database for various applications. QIAGEN Biomedical Knowledge Base (Biomedical KB), a database containing high-quality relationship literature findings, the same database backing Ingenuity Pathway Analysis/IPA) will be used, but learnings can also be applied to similar databases. <p>The following points will be discussed:</p> <p>• Gene set enrichment analysis using Biomedical KB<br> • Target validation through Biomedical KB findings<br> • Potential other use cases, queries and applications requested by registrants</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/96931869/gene-set-enrichment-target"><img src="http://tv.qiagenbioinformatics.com/64968568/96931869/e4fbef5d562098e7b4f091dd31fe5fee/standard/download-10-thumbnail.jpg" width="75" height=""/></a></p> BKB omicsoft webinar http://tv.qiagenbioinformatics.com/photo/79058773/data-curation-as-a-key-element-in <p><p>Learn the 7 habits of effective manual curation that QIAGEN Digital Insights uses to drive and build its data content to advance data science applications in biopharma companies.<br><br>Uses include:<br></p><ul><li><p>biomarker and target identification</p></li><li><p>Disease networks</p></li><li><p>Pathway construction</p></li><li><p>upstream and downstream relationships</p></li></ul></p><p><a href="http://tv.qiagenbioinformatics.com/photo/79058773/data-curation-as-a-key-element-in"><img src="http://tv.qiagenbioinformatics.com/64968556/79058773/5a66f548855b7de1065cd97040cb3f11/standard/download-12-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/79058773 Tue, 07 Feb 2023 17:12:02 GMT Data curation as a key element in successful data science strategy Learn the 7 habits of effective manual curation that QIAGEN Digital Insights uses to drive and build its data content to advance data science applications in biopharma companies.Uses include:biomarker and target identificationDisease networksPathway constructionupstream and downstream relationships Learn the 7 habits of effective manual curation that QIAGEN Digital Insights uses to drive and build its data content to advance data science applications in biopharma companies.Uses include:biomarker and target identificationDisease... tv.qiagenbioinformatics.com 16:14 <p><p>Learn the 7 habits of effective manual curation that QIAGEN Digital Insights uses to drive and build its data content to advance data science applications in biopharma companies.<br><br>Uses include:<br></p><ul><li><p>biomarker and target identification</p></li><li><p>Disease networks</p></li><li><p>Pathway construction</p></li><li><p>upstream and downstream relationships</p></li></ul></p><p><a href="http://tv.qiagenbioinformatics.com/photo/79058773/data-curation-as-a-key-element-in"><img src="http://tv.qiagenbioinformatics.com/64968556/79058773/5a66f548855b7de1065cd97040cb3f11/standard/download-12-thumbnail.jpg" width="75" height=""/></a></p> bkb cancer_drug_discovery omicsoft webinar